{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T06:05:27Z","timestamp":1761717927448,"version":"build-2065373602"},"reference-count":51,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":3882,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p>\n                    <jats:bold>Study Objective.<\/jats:bold>\n                    To review the liver histopathology in transplant recipients who developed hyperbilirubinemia during therapy with quinupristin\u2010dalfopristin, a new streptogramin antibiotic, and to ascertain whether objective histologic evidence of adverse drug effect could be correlated to serum bilirubin levels.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design.<\/jats:bold>\n                    Retrospective analysis.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Setting.<\/jats:bold>\n                    University of Pittsburgh Medical Center.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients.<\/jats:bold>\n                    From a database of 34 liver recipients who received quinupristin\u2010dalfopristin for vancomycin\u2010resistant\n                    <jats:italic>Enterococcus faecium<\/jats:italic>\n                    infection who were prospectively enrolled in a multicenter, open\u2010label, emergency\u2010use protocol, the data for a subset of 25 patients who underwent one or more liver biopsies during therapy were reviewed for this study.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Interventions.<\/jats:bold>\n                    Quinupristin\u2010dalfopristin was administered intravenously at 7.5 mg\/kg every 8 hours. Available serum bilirubin levels from before, during, and 1 week after therapy were tabulated. Liver biopsy results obtained within 1 week before and during therapy were retrospectively reviewed. Histopathologic results were characterized and correlated to bilirubin level.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Measurements and Main Results.<\/jats:bold>\n                    Cholestatic changes were already present in 15 of 17 patients who underwent biopsy before therapy. During therapy, the most common findings from 40 biopsies (25 patients) were cholestasis (33 biopsies), acute rejection (10), and periportal inflammation (8). There was no evidence of drug\u2010specific histopathologic injury.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion.<\/jats:bold>\n                    Hyperbilirubinemia in these patients was likely multifactorial and most frequently due to sepsis and prior graft injury.\n                  <\/jats:p>","DOI":"10.1592\/phco.21.7.661.34580","type":"journal-article","created":{"date-parts":[[2004,6,11]],"date-time":"2004-06-11T09:55:05Z","timestamp":1086947705000},"page":"661-668","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Hyperbilirubinemia during Quinupristin\u2010Dalfopristin Therapy in Liver Transplant Recipients: Correlation with Available Liver Biopsy Results"],"prefix":"10.1002","volume":"21","author":[{"given":"Peter K.","family":"Linden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Bompart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George H.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.1"},{"key":"e_1_2_1_3_2","first-page":"597","article-title":"Nosocomial enterococci resistant to vancomycin: United States 1989\u20131993","volume":"42","author":"Centers for Disease Control and Prevention","year":"1993","journal-title":"MMWR"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/520192"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.4.663"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/23.4.760"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.500030605"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9610(99)00083-5"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/30.suppl_A.67","article-title":"Activity of RP 59500, a new parenteral semisynthetic streptogramin, against staphylococci with various mechanisms of resistance to macrolide\u2010lincosamide\u2010streptogramin antibiotics","volume":"30","author":"Leclercq R.","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/30.suppl_A.19"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(94)00113-B"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00153-3"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.suppl_1.37"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160312"},{"key":"e_1_2_1_15_2","unstructured":"BompartF. DorrM. BekeleT. et al.Overview of the safety and tolerability of quinupristin\/dalfopristin in the global development program [abstr]. In: Program and abstracts of the 20th International Congress of Chemotherapy Sydney Australia June 29 1997;44\u20135."},{"volume-title":"Syncercid (quinupristin\/dalfopristin) integrated summary of safety","year":"1997","author":"Rh\u00f4ne\u2010Poulenc Rorer","key":"e_1_2_1_16_2"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70250-6"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/07315724.1995.10718499"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1040487"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199808150-00005"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(97)70238-5"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90232-1"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840220437"},{"key":"e_1_2_1_24_2","first-page":"G1094","article-title":"Interleukin\u20106 inhibits hepatocyte taurocholate uptake and sodium\u2010potassium\u2010adenosinetriphosphate activity","volume":"267","author":"Green R.M.","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(88)80231-6"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/41.1.61"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1997.tb00507.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8553(21)00234-X"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.33.3.368"},{"key":"e_1_2_1_30_2","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/archinte.1996.00440110099013","article-title":"Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid","volume":"156","author":"Rodriguez L.A. Garcia","year":"1996","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_31_2","first-page":"675","article-title":"Intrahepatic cholestasis due to ticarcillin\u2010clavulanate","volume":"90","author":"Sweet J.M.","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/15.1.179"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(92)90029-O"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/19.5.981"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080080064024"},{"key":"e_1_2_1_36_2","first-page":"1960","article-title":"Cholestatic hepatitis associated with the use of nafcillin","volume":"88","author":"Mazuryk H.","year":"1993","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(94)90830-3"},{"issue":"2","key":"e_1_2_1_38_2","first-page":"76","article-title":"Cholestasis in imipenem\u2010cilastatin treatment","volume":"31","author":"Schreiber C.","year":"1993","journal-title":"Z Gastroenterol"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-81-1-58"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)91013-1"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1980.03300360046027"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1963.tb57105.x"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1177\/106002809202601207"},{"key":"e_1_2_1_44_2","first-page":"1230","article-title":"Cholestatic liver disease with ductopenia (vanishing bile duct syndrome) after administration of clindamycin and trimethoprim\u2010sulfamethoxazole","volume":"89","author":"Altraif I.","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_1_45_2","first-page":"459","article-title":"Cholestatic hepatitis caused by midecamycin","volume":"19","author":"Moreno J.M. Perez","year":"1996","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_1_46_2","first-page":"474","article-title":"Acute cholestatic hepatitis induced by spiramycin","volume":"20","author":"Zuazo J.A.","year":"1997","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_1_47_2","first-page":"217","article-title":"Azithromycin\u2010induced intrahepatic cholestasis","volume":"102","author":"Longo G.","year":"1997","journal-title":"Am J Med"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/44.2.251"},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-8553(21)00226-0","article-title":"General aspects of drug\u2010induced liver disease","volume":"24","author":"Zimmerman H.J.","year":"1995","journal-title":"Gastroenterol Clin North Am"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb05785.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.suppl_1.129"},{"key":"e_1_2_1_52_2","unstructured":"TalbotG.H. ZhuG.R.Characterization of arthralgia\/myalgia associated with quinupristin\/dalfopristin (Q\/D Synercid) [abstr]. In: Program and abstracts of the 36th annual meeting of the Infectious Diseases Society of America 1998:120."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.21.7.661.34580","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.21.7.661.34580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:53:39Z","timestamp":1761065619000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.21.7.661.34580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1592\/phco.21.7.661.34580"],"URL":"https:\/\/doi.org\/10.1592\/phco.21.7.661.34580","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2001,6]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}